Summary
In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane™) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM). In parallel, we also sought to determine to what extent the outcomes from this clinical trial correlated with the findings from studies utilizing two murine intracerebral GBM models, U87MG and U251HF, to determine the predictive value of these murine models. In the clinical trial, 25 patients were studied at recurrence. Stable disease, which occurred in 44% of the patients, was the best response. The median progression-free survival (PFS) was 8 weeks, with a PFS at 6 months of only 19%. For the patients with stable disease, the median PFS was 24 weeks. The toxicity profile was unremarkable. The modest effect on PFS seen in this study agreed with the recent findings of another study, which showed a 19% PFS at 6 months in patients treated with 13-cRA alone. Thus, the combination of 13-cRA with celecoxib is not more effective than 13-cRA in the treatment of progressive GBM. In the murine model study, we found that long-term dosing with 13-cRA or celecoxib alone or in combination did not increase survival in animals with U87MG tumors but modestly increased survival in animals with U251HF tumors. There was no evidence of synergism between the two drugs. From this, we concluded that the animal studies generally predicted that the two agents would have only a modest effect alone and no additive effect when given in combination to patients.
Similar content being viewed by others
Abbreviations
- 13-cRA:
-
13-cis-retinoic acid or isotretinoin
- COX-2:
-
cyclooxygenase-2
- EGFR:
-
endothelial growth factor (EGF) receptor
- GBM:
-
glioblastoma multiforme
- IRB:
-
Internal review board
References
Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, pp 2100–2160
Berger MS, Leibel SA, Bruner JM, Finlay JL, Levin VA: Primary cerebral tumors. In: Levin VA (ed) Cancer in the Nervous System. Oxford University Press, New York, pp 75–148
Yung WK, Kyritsis AP, Gleason MJ, Levin VA, Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid Clin Cancer Res 2: 1931–1935 1996
Groves MD, Jaeckle KA, Kyritsis AP, Yung WKA, Levin VA: Cis-retinoic acid for the treatment of recurrent glioblastoma multiforme Neuro-Oncol 1: 314, 1999
See SJ, Levin VA, Yung WK, Hess KR, Groves MD: 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme Neuro-oncol 6: 253–258 2004
Preis PN, Saya H, Nadasdi L, Hochhaus G, Levin V, Sadee W: Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin A Cancer Res 48: 6530–6534, 1988
Maria BL, Steck PA, Yung WK, Milici A, Bruner JM, Pathak S, Becker FF: The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen J Neurooncol 7: 329–338, 1989
Steck PA, Hadi A, Lotan R, Yung WK, Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells J Cell Biochem 42: 83–94, 1990
Yung WK, Lotan R, Lee P, Lotan D, Steck PA: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells Cancer Res 49: 1014–1019, 1989
Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WKA: The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin) J Neurooncol 34: 145–151, 1997
Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R, Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo Acta Neuropathol (Berl) 98: 240–244, 1999
Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Res 61: 4375–4381, 2001
Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PM: Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398 Cancer Res 60: 4926–4931, 2000
Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH: Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines Cancer Biol Ther 3: 55–62, 2004
Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ: Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells Cancer Res 57: 2890–2895, 1997
Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8: 1277–1280, 1990
Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP: Fenretinide activates caspases and induces apoptosis in gliomas Clin Cancer Res 5: 2230–2235, 1999
Chattopadhyay N, Butters RRJ, Brown EM: Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells Mol Brain Res 87: 100–108, 2001
Acknowledgement
We would like to thank Betty Notzon for editorial assistance and Melissa McLane for manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levin, V., Giglio, P., Puduvalli, V. et al. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78, 85–90 (2006). https://doi.org/10.1007/s11060-005-9062-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-9062-4